Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma
Am J Hematol
.
2021 Oct 1;96(10):E386-E389.
doi: 10.1002/ajh.26293.
Epub 2021 Jul 29.
Authors
Arushi Khurana
1
,
Matthew Hathcock
1
,
Thomas M Habermann
1
,
Abdullah S Al Saleh
2
,
Sangeetha Gandhi
1
,
Tuan Truong
1
,
N Nora Bennani
1
,
Jonas Paludo
1
,
Jose C Villasboas
1
,
Stephen M Ansell
1
,
David J Inwards
1
,
Luis F Porrata
1
,
Patrick B Johnston
1
,
Ivana Micallef
1
,
Yi Lin
1
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
2
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
PMID:
34260759
DOI:
10.1002/ajh.26293
No abstract available
Publication types
Letter
MeSH terms
Humans
Immunotherapy, Adoptive
Lymphoma, Non-Hodgkin / therapy*
Middle Aged
Retrospective Studies
Stem Cell Transplantation
Transplantation, Autologous
Treatment Outcome